Related Experiment Video
Updated: Jan 22, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer Patients
Lucía Oliva1, Rebeca Lozano2, Casilda Llácer1
1UGCI Oncología Médica, Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Málaga, Spain; CNIO-IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Malaga, Málaga, Spain.
Predictive models for BRCA1/2 mutations underperform in prostate cancer (PC) patients. These tools should not guide genetic testing in men with PC, as they miss many mutation carriers.
Area of Science:
- Oncology
- Genetics
- Preventive Medicine
Background:
- Germline BRCA1/2 mutations are crucial for prostate cancer (PC) management and hereditary cancer prevention in relatives.
- Existing prediction tools (BRCAPRO, Manchester scoring system [MSS]) optimize genetic screening in breast and ovarian cancer.
- The utility of these models for identifying BRCA1/2 mutations in PC patients remains unclear.
Purpose of the Study:
- To evaluate the performance of BRCAPRO and MSS in identifying PC patients with known germline BRCA1/2 mutations.
- To determine the proportion of PC patients with BRCA1/2 mutations who would meet testing criteria based on these models.
Main Methods:
- Analysis of 106 families with known BRCA1/2 mutations, including 23 families with PC cases.
- Assessment of PC patients against BRCAPRO and MSS criteria for germline mutation testing eligibility.
Main Results:
- Only 30% of PC patients with known BRCA1/2 mutations qualified for testing via BRCAPRO.
- 48% of PC patients with known BRCA1/2 mutations qualified for testing via MSS.
- A significant number of breast and/or ovarian cancer cases occurred in families before the PC case led to genetic testing.
Conclusions:
- BRCAPRO and MSS demonstrate suboptimal performance in identifying male PC patients with germline BRCA1/2 mutations.
- Current risk assessment models are not suitable for optimizing genetic testing in prostate cancer.
- Further research is needed to develop accurate prediction tools for hereditary cancer syndromes in PC patients.
Related Concept Videos
Predicting Products: SN1 vs. SN2
With increased substitution on the alkyl halide,...
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Cancers Originate from Somatic Mutations in a Single Cell
Viral Mutations
Predicting Molecular Geometry

